Thierry Andre, MD, discusses the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer and the safety profiles of the 2 arms of the phase 3 SOLSTICE trial.
Three studies provide more data on risk for major adverse cardiovascular events with JAK inhibitors vs TNF inhibitors, as well as their efficacy in patients with different levels of risk.